{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012793","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.526547+00:00","generated_at":"2026-05-31T04:39:50.971962+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PBFT02 shows robust CSF progranulin increase; well-tolerated with enhanced immunosuppression","bullets":["CSF PGRN up to 6-fold at month 1 (10.7-17.3 ng/mL) and up to 10-fold at month 6 (21.7-27.3 ng/mL), exceeding healthy controls (3.3-8.2 ng/mL).","No serious adverse events in patients 2-5 with enhanced immunosuppression; first patient had SAEs with lower steroid regimen.","CSF PGRN remained elevated at 12 months (34.2 ng/mL), with rate of increase slowing from 58% to 26% between months 1-6 and 6-12.","Cohort 2 currently enrolling; Cohort 4 anticipated to open in first half of 2025 for FTD-C9orf72.","Plasma PGRN expression remained below healthy reference levels across all five patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012793","json":"https://secwatch.observer/filing/0001558370-24-012793.json","markdown":"https://secwatch.observer/filing/0001558370-24-012793.md","text":"https://secwatch.observer/filing/0001558370-24-012793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/0001558370-24-012793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/pasg-20240916x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:39:50.971962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}